[go: up one dir, main page]

WO2009152484A3 - Methods and platforms for drug discovery - Google Patents

Methods and platforms for drug discovery Download PDF

Info

Publication number
WO2009152484A3
WO2009152484A3 PCT/US2009/047291 US2009047291W WO2009152484A3 WO 2009152484 A3 WO2009152484 A3 WO 2009152484A3 US 2009047291 W US2009047291 W US 2009047291W WO 2009152484 A3 WO2009152484 A3 WO 2009152484A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
identifying
health condition
platforms
drug discovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/047291
Other languages
French (fr)
Other versions
WO2009152484A2 (en
Inventor
Kazuhiro Sakurada
Kenneth J. Seidenman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
iZumi Bio Inc
Original Assignee
iZumi Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by iZumi Bio Inc filed Critical iZumi Bio Inc
Priority to EP09763772A priority Critical patent/EP2297332A4/en
Priority to CN2009801275028A priority patent/CN102203275A/en
Publication of WO2009152484A2 publication Critical patent/WO2009152484A2/en
Publication of WO2009152484A3 publication Critical patent/WO2009152484A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the risk of drug toxicity in a human subject, and methods for identifying a candidate gene that contributes to a human disease. The invention also discloses human induced pluripotent stem cell lines.
PCT/US2009/047291 2008-06-13 2009-06-12 Methods and platforms for drug discovery Ceased WO2009152484A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09763772A EP2297332A4 (en) 2008-06-13 2009-06-12 METHODS AND PLATFORMS FOR DISCOVERING MEDICINES
CN2009801275028A CN102203275A (en) 2008-06-13 2009-06-12 Drug Discovery Methods and Platforms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6159408P 2008-06-13 2008-06-13
US6159208P 2008-06-13 2008-06-13
US61/061,594 2008-06-13
US61/061,592 2008-06-13

Publications (2)

Publication Number Publication Date
WO2009152484A2 WO2009152484A2 (en) 2009-12-17
WO2009152484A3 true WO2009152484A3 (en) 2010-03-11

Family

ID=41417418

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/047291 Ceased WO2009152484A2 (en) 2008-06-13 2009-06-12 Methods and platforms for drug discovery
PCT/US2009/047293 Ceased WO2009152485A2 (en) 2008-06-13 2009-06-12 Methods of cell-based technologies

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047293 Ceased WO2009152485A2 (en) 2008-06-13 2009-06-12 Methods of cell-based technologies

Country Status (3)

Country Link
EP (1) EP2297332A4 (en)
CN (1) CN102203275A (en)
WO (2) WO2009152484A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451837B1 (en) * 2009-07-08 2015-03-25 Cellular Dynamics International, Inc. Modified ips cells having a mutant form of human immunodeficiency virus (hiv) cellular entry gene
WO2011119942A1 (en) * 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
JP5988961B2 (en) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ Methods for generating cardiomyocytes
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
US9410128B2 (en) 2011-02-22 2016-08-09 Sanford-Burnham Medical Research Institute Method and compounds for generation of iPSCs
JP6298405B2 (en) 2011-08-30 2018-03-20 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ Method for generating cardiomyocytes
HK1258207A1 (en) * 2015-10-05 2019-11-08 Orig3N, Inc. Diagnosis and treatment of parkinson's disease based on identification and amelioration of liver dysfunction
CN107603951B (en) * 2016-07-12 2020-08-14 中国人民解放军军事医学科学院基础医学研究所 Novel growth/neurotrophic factor composition for in vivo induction of mature neuronal division and use thereof
GB201708554D0 (en) * 2017-05-30 2017-07-12 Queens Univ Of Belfast A method for the generation of induced pluirpotent stem cells
US11227692B2 (en) * 2017-12-28 2022-01-18 International Business Machines Corporation Neuron model simulation
GB2583309A (en) * 2017-12-28 2020-10-21 Ibm Neuron model generation for personalised drug treatment
CN109294975A (en) * 2018-10-23 2019-02-01 山东华思生物科技有限公司 A kind of stem cell drugs screening technique
WO2020118158A1 (en) * 2018-12-07 2020-06-11 President And Fellows Of Harvard College Drug discovery and early disease identification platform using electronic health records, genetics and stem cells
SG11202106673XA (en) * 2018-12-21 2021-07-29 I Peace Inc Health risk information management device, health risk information management method, and program
CN111621546A (en) * 2020-06-18 2020-09-04 上海诚益生物科技有限公司 Method for screening thyroxine receptor agonist by using primary hepatocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365352B1 (en) * 1997-08-22 2002-04-02 Yale University Process to study changes in gene expression in granulocytic cells
US20040048297A1 (en) * 2002-07-30 2004-03-11 Gene Logic, Inc. Nucleic acid detection assay control genes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033297A1 (en) * 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
WO2005095583A1 (en) * 2004-03-03 2005-10-13 Life-Sciences Ag Large scale storage of viable somatic stem and/or progenitor cells
CN1961283A (en) * 2004-03-26 2007-05-09 细胞基因公司 Systems and methods for providing a stem cell bank
US20090074731A1 (en) * 2007-09-13 2009-03-19 Librach Clifford L Method of isolation and use of cells derived from first trimester umbilical cord tissue
WO2009061442A1 (en) * 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365352B1 (en) * 1997-08-22 2002-04-02 Yale University Process to study changes in gene expression in granulocytic cells
US20040048297A1 (en) * 2002-07-30 2004-03-11 Gene Logic, Inc. Nucleic acid detection assay control genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAZUTOSHI TAKAHASHI ET AL.: "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors", CELL, vol. 131, 30 November 2007 (2007-11-30), pages 1 - 12, XP002555952 *
See also references of EP2297332A4 *
W.E. LOWRY ET AL.: "Generation of human induced pluripotent stem cells from dermal fibroblasts", PNAS, vol. 105, no. 8, 26 February 2008 (2008-02-26), pages 2883 - 2888, XP002555951 *

Also Published As

Publication number Publication date
EP2297332A4 (en) 2012-03-21
CN102203275A (en) 2011-09-28
WO2009152484A2 (en) 2009-12-17
WO2009152485A2 (en) 2009-12-17
EP2297332A2 (en) 2011-03-23
WO2009152485A3 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
WO2009152484A3 (en) Methods and platforms for drug discovery
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2011038155A3 (en) Genetic analysis
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2010065557A3 (en) Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
WO2009117122A8 (en) Genetic analysis
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2009025852A3 (en) Methods of using mirna for detection of in vivo cell death
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2008023266A3 (en) Kiwi extract
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008027428A3 (en) Gene expression profiling for identification, monitoring and treatment of transplant rejection
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
EP2361233A4 (en) Diatomaceous earth products containing reduced soluble metal levels, processes for reducing soluble metal levels in diatomaceous earth products, and methods of using the same
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
WO2007149982A3 (en) Diagnosis of autoimmune disease
WO2010092164A3 (en) Bacterial dna as markers of cardiovascular and/or metabolic disease
WO2006058048A3 (en) Method of determining a cellular response to a biological agent
WO2010004283A3 (en) Sulfonylurea receptor and means for treating ischaemia
WO2009082445A3 (en) Novel devices for the detection of the presence and/or activity of proteases in biological samples
WO2011028099A3 (en) Method for preparing an invasive test of an egg and for determining a gender of an embryo in an egg

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980127502.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763772

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009763772

Country of ref document: EP